2019
The nonsurgical management of upper tract urothelial carcinoma: A role for active surveillance?
Syed J, Nguyen K, Javier-Desloges J, Leapman M, Raman J, Shuch B. The nonsurgical management of upper tract urothelial carcinoma: A role for active surveillance? Journal Of Clinical Oncology 2019, 37: 485-485. DOI: 10.1200/jco.2019.37.7_suppl.485.Peer-Reviewed Original ResearchUpper tract urothelial cancerMedian overall survivalOverall survivalTumor gradeCox proportional hazards regression modelProportional hazards regression modelsNational Cancer DatabaseKaplan-Meier methodHazards regression modelsHigh-grade tumorsGovernment health insuranceDefinitive surgeryDefinitive therapyOlder patientsPatient demographicsMedian ageWorse survivalUrothelial cancerGrade tumorsAlternative therapiesCancer DatabaseOS differenceRadiation therapyPatientsSurvival analysis
2018
National determinants of active surveillance among patients with clinical stage 1A kidney tumors.
Lu A, Nguyen K, Nolte A, Alimi O, Hsiang W, Ghabili K, Syed J, Shuch B, Leapman M. National determinants of active surveillance among patients with clinical stage 1A kidney tumors. Journal Of Clinical Oncology 2018, 36: 694-694. DOI: 10.1200/jco.2018.36.6_suppl.694.Peer-Reviewed Original ResearchSmall renal massesNational Cancer DatabaseActive surveillanceInitial managementRenal massesCancer DatabaseClinical T1a renal massesMultivariate logistic regression modelFacility-level differencesWest North Central census divisionCancer registry dataT1a renal massesLogistic regression modelsSocio-demographic determinantsDefinitive therapyDefinitive treatmentPatient ageTotal cohortPractice patternsNational utilizationRegistry dataInclusion criteriaCaucasian raceKidney tumorsPatients
2016
Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes
Leapman MS, Cowan JE, Simko J, Roberge G, Stohr BA, Carroll PR, Cooperberg MR. Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. European Urology 2016, 71: 750-759. PMID: 27940155, DOI: 10.1016/j.eururo.2016.11.032.Peer-Reviewed Original ResearchConceptsRisk of PCSMGleason grade groupBone metastasesProstate Strategic Urologic Research Endeavor (CaPSURE) registryGroup ICox proportional hazards modelGrade groupBone metastatic progressionGrade group IPrimary androgen deprivationPrognostic grade groupingKaplan-Meier methodProstate cancer outcomesProportional hazards modelGroup VProstate cancer pathologyNondefinitive therapyDefinitive therapyConservative managementUnadjusted riskAndrogen deprivationGleason sumGleason scoreCancer outcomesGrouping systemRelationship of phosphodiesterase type 5 inhibitor to biochemical recurrence after definitive therapy for prostate cancer.
Leapman M, Cowan J, Nguyen H, Porten S, Cooperberg M, Carroll P. Relationship of phosphodiesterase type 5 inhibitor to biochemical recurrence after definitive therapy for prostate cancer. Journal Of Clinical Oncology 2016, 34: 119-119. DOI: 10.1200/jco.2016.34.2_suppl.119.Peer-Reviewed Original ResearchPhosphodiesterase type 5 inhibitorsBiochemical recurrenceType 5 inhibitorsProstate cancerUse of PDE5iMedian age 61 yearsMedian age 69 yearsProstate Strategic Urologic Research EndeavorRisk of BCRCox proportional hazards modelAndrogen deprivation therapyAge 61 yearsAge 69 yearsKaplan-Meier methodSexual function scoresCohort of menProportional hazards modelDeprivation therapyPrescription complianceDefinitive therapyTime-dependent useDefinitive treatmentDisease recurrenceClinical evidenceBaseline useChange in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance.
Leapman M, Cowan J, Nguyen H, Cooperberg M, Carroll P. Change in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2016, 34: 124-124. DOI: 10.1200/jco.2016.34.2_suppl.124.Peer-Reviewed Original ResearchGenomic Prostate ScoreAdverse pathological findingsActive surveillanceProstate cancerRadical prostatectomyPathological findingsFavorable-risk prostate cancerIntermediate-risk prostate cancerIntermediate clinical riskNCCN risk classificationSerial prostate biopsyRisk prostate cancerSubsequent clinical outcomesTime of surgeryRT-PCR assaysPT3a diseaseDefinitive therapyIntermediate riskOncologic outcomesClinical outcomesAdverse pathologySerial biopsiesProstate biopsyMedian changeSerial changes